Decision: Favourable

Decisions Table

Study Title:

A Phase 1/2, Multi-center, Open-label Study of IMGN632 Monotherapy Administered Intravenously in Patients with CD123-positive Acute Myeloid Leukemia and Other CD123-positive Hematologic Malignancies

  • NREC Code:

    22-NREC-CT-156

  • Decision:

    Favourable

  • Meeting Date:

    05/10/2022

  • Study Type:

    NREC CT

  • Principal Investigator:

    Dr. Nina Orfali

  • PI Institution:

    St James's Hospital

  • Sponsor:

    ImmunoGen, Inc.,

Scroll to Top